Activists hold signs containing the image of Turing Pharmaceuticals CEO Martin Shkreli in front the building that houses Turing’s offices, in New York, during a protest highlighting pharmaceutical drug pricing on Oct. 1. After weeks of criticism from patients, doctors and even other drugmakers for hiking a life-saving medicine’s price more than fiftyfold, Turing Pharmaceuticals is reneging on its pledge to cut the $750-per-pill price. But a competitor’s 99-cent capsule version is selling well. (Craig Ruttle, Associated Press file)
Re: “Turing suggests it won’t cut drug price,” Nov. 25 business news brief.
Thank you for the update on Turing Pharmaceuticals’ unconscionable apparent market manipulation and subsequent price increase of Daraprim from $13.50 to $750 per pill. I’m sure Turing wishes this exposure of their gross greed and market exploitation of America’s sick would simply go away. Thankfully, The Post and other media continue to follow this story.
This is one case where there really oughta be a law. That Turing’s spokesman states, “A reduction in Daraprim’s list price would not translate into a benefit for patients,” is outrageous and shocking. I can’t imagine many self-paying patients (or insurance companies) who would prefer to pay $750 per pill instead of the previous $13.50.
Richard Bursell, Colorado Springs
This letter was published in the Dec. 4 edition.
Submit a letter to the editor via this form or check out our guidelines for how to submit by e-mail or mail.
